Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Jacob Laubach"'
Autor:
Pamela S. Becker, Michael D. Robbins, Peter Sabbatini, Stacey Chuma, Kalvis Hornburg, Kaitlen Reyes, Alexandra Savell, Patrick Henrick, Jacob Laubach, Kenneth C. Anderson, Paul G. Richardson, Romanos Sklavenitis-Pistofidis, Oksana Zavidij, Rachid Baz, Raymond P. Perez, Robert A. Redd, Chia-Jen Liu, Irene M. Ghobrial
This file contains the legends for the supplementary figures.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::403647a09b3635dce22c4f3b8c519b1a
https://doi.org/10.1158/1078-0432.22473741
https://doi.org/10.1158/1078-0432.22473741
Autor:
David Avigan, Donald Kufe, Kenneth Anderson, Jacob Rowe, Viki Held, Lina Bisharat, Yan Emily Yuan, Vassiliki Boussiotis, Noopur Raje, Jacob Laubach, Paul Richardson, Dimitrios Tzachanis, James D. Levine, Robin Joyce, Edie Weller, Federico Campigotto, Heidi Mills, Poorvi Somaiya, Bimalangshu R. Dey, Tami Katz, Nikhil C. Munshi, Lynne Uhl, Baldev Vasir, Irit Avivi, Jacalyn Rosenblatt
PDF file - 522K, Percentage of CD8+T cells recognizing MUC1 tetramer in HLA 2.1+ patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04bf3b43e4e929fad1e7ca4d48bfe971
https://doi.org/10.1158/1078-0432.22451159.v1
https://doi.org/10.1158/1078-0432.22451159.v1
Autor:
Pamela S. Becker, Michael D. Robbins, Peter Sabbatini, Stacey Chuma, Kalvis Hornburg, Kaitlen Reyes, Alexandra Savell, Patrick Henrick, Jacob Laubach, Kenneth C. Anderson, Paul G. Richardson, Romanos Sklavenitis-Pistofidis, Oksana Zavidij, Rachid Baz, Raymond P. Perez, Robert A. Redd, Chia-Jen Liu, Irene M. Ghobrial
Purpose:Ulocuplumab (BMS-936564) is a first-in-class fully human IgG4 monoclonal anti-CXCR4 antibody that inhibits the binding of CXCR4 to CXCL12.Patients and Methods:This phase Ib/II study aimed to determine the safety and tolerability of ulocupluma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54d7c946d4f8b2b3fdf89b50a1279664
https://doi.org/10.1158/1078-0432.c.6528591
https://doi.org/10.1158/1078-0432.c.6528591
Autor:
Pamela S. Becker, Michael D. Robbins, Peter Sabbatini, Stacey Chuma, Kalvis Hornburg, Kaitlen Reyes, Alexandra Savell, Patrick Henrick, Jacob Laubach, Kenneth C. Anderson, Paul G. Richardson, Romanos Sklavenitis-Pistofidis, Oksana Zavidij, Rachid Baz, Raymond P. Perez, Robert A. Redd, Chia-Jen Liu, Irene M. Ghobrial
The figures show that patients received 10 mg ulocuplumab could reach higher concentration peak and larger dose-corrected area under curve (both p < 0.001).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::153ca41d7fcc6ab8e1b99fc0d6f3904f
https://doi.org/10.1158/1078-0432.22473753.v1
https://doi.org/10.1158/1078-0432.22473753.v1
Autor:
Pamela S. Becker, Michael D. Robbins, Peter Sabbatini, Stacey Chuma, Kalvis Hornburg, Kaitlen Reyes, Alexandra Savell, Patrick Henrick, Jacob Laubach, Kenneth C. Anderson, Paul G. Richardson, Romanos Sklavenitis-Pistofidis, Oksana Zavidij, Rachid Baz, Raymond P. Perez, Robert A. Redd, Chia-Jen Liu, Irene M. Ghobrial
This figure shows Absolute cell numbers in the peripheral blood of patients receiving 10mg/kg ulocuplumab (absolute count, cells/uL).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61f08c65058363e1de82e8b0fc83392e
https://doi.org/10.1158/1078-0432.22473744
https://doi.org/10.1158/1078-0432.22473744
Autor:
Pamela S. Becker, Michael D. Robbins, Peter Sabbatini, Stacey Chuma, Kalvis Hornburg, Kaitlen Reyes, Alexandra Savell, Patrick Henrick, Jacob Laubach, Kenneth C. Anderson, Paul G. Richardson, Romanos Sklavenitis-Pistofidis, Oksana Zavidij, Rachid Baz, Raymond P. Perez, Robert A. Redd, Chia-Jen Liu, Irene M. Ghobrial
This figure shows (A) Proportion of circulating CD34+ stem cells (% of living cells, all patients combined). (B) Proportion of circulating CD138+ myeloma cells (% of living cells, all patients combined) (C) Distribution of CD34+ stem cells in respond
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64d55193434afd6c9a2660c69f9aed4d
https://doi.org/10.1158/1078-0432.22473750
https://doi.org/10.1158/1078-0432.22473750
Autor:
David Avigan, Donald Kufe, Kenneth Anderson, Jacob Rowe, Viki Held, Lina Bisharat, Yan Emily Yuan, Vassiliki Boussiotis, Noopur Raje, Jacob Laubach, Paul Richardson, Dimitrios Tzachanis, James D. Levine, Robin Joyce, Edie Weller, Federico Campigotto, Heidi Mills, Poorvi Somaiya, Bimalangshu R. Dey, Tami Katz, Nikhil C. Munshi, Lynne Uhl, Baldev Vasir, Irit Avivi, Jacalyn Rosenblatt
Purpose: A multiple myeloma vaccine has been developed whereby patient-derived tumor cells are fused with autologous dendritic cells, creating a hybridoma that stimulates a broad antitumor response. We report on the results of a phase II trial in whi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::008e112b659829c9a6b5df166a140425
https://doi.org/10.1158/1078-0432.c.6522116
https://doi.org/10.1158/1078-0432.c.6522116
Autor:
Pamela S. Becker, Michael D. Robbins, Peter Sabbatini, Stacey Chuma, Kalvis Hornburg, Kaitlen Reyes, Alexandra Savell, Patrick Henrick, Jacob Laubach, Kenneth C. Anderson, Paul G. Richardson, Romanos Sklavenitis-Pistofidis, Oksana Zavidij, Rachid Baz, Raymond P. Perez, Robert A. Redd, Chia-Jen Liu, Irene M. Ghobrial
This figure presents a consort diagram showing (A) the dose-escalation scheme for BMS-936564 (ulocuplumab), (B) the dose-expansion scheme, including Arms A & B, of the study and (C) Number of patients at each dose level in the phase I and II studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b5a4c5a0bde393f0e59926e66f78ad8
https://doi.org/10.1158/1078-0432.22473756.v1
https://doi.org/10.1158/1078-0432.22473756.v1
Autor:
Yuji Mishima, Bruno Paiva, Jiantao Shi, Mira Massoud, Salomon Manier, Adriana Perilla-Glen, Yosra Aljawai, Satoshi Takagi, Daisy Huynh, Aldo Roccaro, Antonio Sacco, Diego Alignani, Maria-Victoria Mateos, Joan Blade, Juan-Jose Lahuerta, Paul Richardson, Jacob Laubach, Robert Schlossman, Kenneth Anderson, Nikhil Munshi, Felipe Prosper, Jesus San Miguel, Franziska Michor, Irene M. Ghobrial
Publikováno v:
Molecular Cancer Therapeutics. 14:A82-A82
Introduction: Genomic sequencing of tumor cells obtained from the bone marrow (BM) of patients with multiple myeloma (MM) has demonstrated significant clonal heterogeneity. However, it could be envisioned that such clonal diversity may be even higher